NO20053991L - Piperazin-2-karboksamidderivater - Google Patents

Piperazin-2-karboksamidderivater

Info

Publication number
NO20053991L
NO20053991L NO20053991A NO20053991A NO20053991L NO 20053991 L NO20053991 L NO 20053991L NO 20053991 A NO20053991 A NO 20053991A NO 20053991 A NO20053991 A NO 20053991A NO 20053991 L NO20053991 L NO 20053991L
Authority
NO
Norway
Prior art keywords
piperazine
carboxamide
labor
dysmenorrhea
prophylaxis
Prior art date
Application number
NO20053991A
Other languages
English (en)
Norwegian (no)
Inventor
Matthias Schwarz
Patrick Page
Russel J Thomas
Catherine Jorand-Lebrun
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20053991L publication Critical patent/NO20053991L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20053991A 2003-02-14 2005-08-26 Piperazin-2-karboksamidderivater NO20053991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003422 2003-02-14
PCT/EP2004/050093 WO2004071390A2 (fr) 2003-02-14 2004-02-06 Derives de piperazine-2-carboxamide

Publications (1)

Publication Number Publication Date
NO20053991L true NO20053991L (no) 2005-08-26

Family

ID=32864935

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053991A NO20053991L (no) 2003-02-14 2005-08-26 Piperazin-2-karboksamidderivater

Country Status (10)

Country Link
US (1) US8404690B2 (fr)
EP (1) EP1592389B1 (fr)
JP (1) JP4825664B2 (fr)
AT (1) ATE429228T1 (fr)
AU (1) AU2004212335A1 (fr)
CA (1) CA2513716A1 (fr)
DE (1) DE602004020734D1 (fr)
ES (1) ES2324535T3 (fr)
NO (1) NO20053991L (fr)
WO (1) WO2004071390A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511488B1 (fr) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Inhibiteurs humains d'adam 10
US7754722B2 (en) * 2002-09-20 2010-07-13 Merck Serono Sa Piperazine derivatives and methods of use
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
EP2044038B1 (fr) * 2006-06-06 2014-07-02 Cornerstone Therapeutics Inc. Nouvelles pipérazines, compositions pharmaceutiques et procédés d'utilisation de celles-ci
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2254564A1 (fr) 2007-12-12 2010-12-01 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JP6902466B2 (ja) * 2014-11-07 2021-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ミオカルディン関連転写因子および血清応答因子(mrtf/srf)媒介性遺伝子転写の阻害剤ならびにその使用方法
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2019104011A1 (fr) * 2017-11-21 2019-05-31 Biomarin Pharmaceutical Inc. Inhibiteurs de la céramide galactosyltransférase pour le traitement de maladies
WO2020028221A1 (fr) * 2018-07-30 2020-02-06 Biomarin Pharmaceutical Inc. Inhibiteurs de la céramide galactosyltransférase pour le traitement d'une maladie
WO2021037699A1 (fr) * 2019-08-26 2021-03-04 Société des Produits Nestlé S.A. Myo-inositol et prévention de la naissance prématurée
WO2021037698A1 (fr) * 2019-08-26 2021-03-04 Société des Produits Nestlé S.A. Myo-inositol et prévention la rpmat
WO2023215205A1 (fr) * 2022-05-06 2023-11-09 Merck Sharp & Dohme Llc Agonistes du récepteur de l'orexine
WO2024107615A1 (fr) * 2022-11-17 2024-05-23 Merck Sharp & Dohme Llc Agonistes du récepteur de l'orexine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6450818A (en) 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
US6271201B1 (en) * 1993-07-15 2001-08-07 Board Of Regents, The University Of Texas System Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I
TW472047B (en) 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
US5612484A (en) * 1995-05-18 1997-03-18 Merck & Co., Inc. Process for making HIV protease inhibitors
EP1095936B1 (fr) * 1995-12-08 2004-11-24 Agouron Pharmaceuticals, Inc. Intermédiaires servant à la préparation d' inhibiteurs de métalloproteinases
DE69926078T2 (de) * 1998-12-23 2006-04-20 Schering Corp. Farnesyl-protein transferase inhibitoren
WO2000077519A1 (fr) * 1999-06-15 2000-12-21 Aventis Pharmaceuticals Products Inc. Synthese en phase solide de derives de diazacycloalkylcarboxy n,n-disubstitues
WO2002026720A2 (fr) * 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. INHIBITEURS DE FACTOR Xa A BASE DE PIPERAZINE
AU2002248322B2 (en) 2001-01-24 2005-06-09 The Arizona Board Of Regents, On Behalf Of, The University Of Arizona Methods for screening for substances which inhibit FP prostanoid receptor interaction with a compound having PGF2alphaalphaactivity and methods of treating cancer
US7754722B2 (en) 2002-09-20 2010-07-13 Merck Serono Sa Piperazine derivatives and methods of use

Also Published As

Publication number Publication date
ES2324535T3 (es) 2009-08-10
EP1592389B1 (fr) 2009-04-22
ATE429228T1 (de) 2009-05-15
JP4825664B2 (ja) 2011-11-30
AU2004212335A1 (en) 2004-08-26
US8404690B2 (en) 2013-03-26
DE602004020734D1 (de) 2009-06-04
WO2004071390A3 (fr) 2004-12-23
CA2513716A1 (fr) 2004-08-26
US20070142391A1 (en) 2007-06-21
WO2004071390A2 (fr) 2004-08-26
AU2004212335A8 (en) 2004-08-26
JP2006517566A (ja) 2006-07-27
EP1592389A2 (fr) 2005-11-09

Similar Documents

Publication Publication Date Title
NO20053991L (no) Piperazin-2-karboksamidderivater
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
EA200401270A1 (ru) Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
CY1113736T1 (el) Ετεροαρυλ-ουριες και η χρηση τους ως ενεργοποιητες γλυκοκινασης
MY140031A (en) Carbonyl compounds
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
BRPI0606740A2 (pt) compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos
MXPA05013536A (es) Derivados de etinilprolina.
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
NO20050063L (no) 2-heteroaryl karboksamider
ECSP055844A (es) Nuevos compuestos triciclicos
WO2003106450A8 (fr) Phenylaminopyrimidines et leur utilisation en tant qu'inhibiteurs de la rho-kinase
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
ATE349448T1 (de) Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
TW200609222A (en) Diazole derivatives
UA85676C2 (en) Carbonyl compounds
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
ATE371662T1 (de) Siliziumverbindungen und deren verwendung
EA200601456A1 (ru) Способ получения пирролидиноксимов

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application